Trials / Completed
CompletedNCT01472003
An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types
An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types Likely to Express Epidermal Growth Factor Receptor (EGFR)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label study designed to evaluate the biodistribution and imaging characteristics of ABT-806i (111In-ABT-806) in subjects with advanced solid tumor types.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-806 | ABT-806 will be administered by intravenous infusion. |
| DRUG | ABT-806i | ABT-806i will be administered by intravenous infusion. |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2011-11-16
- Last updated
- 2013-01-14
Locations
2 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT01472003. Inclusion in this directory is not an endorsement.